Aquestive Therapeutics announced the appointment of Abigail Jenkins to the Company’s Board of Directors, effective April 1, 2024. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. Aquestive’s Board of Directors will now be comprised of eight directors, seven of whom are independent directors. Jenkins, M.S., is President and Chief Executive Officer of Gamida Cell (GMDA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics initiated with an Outperform at Raymond James
- Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
- Aquestive Therapeutics 16.667M share Spot Secondary priced at $4.50
- Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
- Aquestive Therapeutics Announces Proposed Public Offering of Common Stock